Fast Locator 2012-2013: Suzhou Pharma Services - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Fast Locator 2012-2013: Suzhou Pharma Services

Suzhou Pharma Outsourcing Services

Suzhou Pharma Services
9 Polito Ave., Suite 900
Lyndhurst, NJ 07071
tel. 732.993.9822

Sales Contact:

Marc Finn

Year Founded:


Regions where services are provided:

North America, Asia.

Number of Employees:


Annual Revenues:

$0–10 million

Outsourcing services provided:

Analytical Services

  • Chemistry & stability
  • Particle characterization
  • Product characterization

Commercial Manufacturing

  • Ingredient processing
  • Solid-dose manufacturing

Consulting Services

  • Project & sourcing management
  • Regulatory, Validation, IT, & QA/QC Services

Development and Phase I/II CTM

  • Solid-dose, semisolids, & liquids development

Packaging & Logistics

  • Clinical labels
  • Clinical packaging & distribution
  • Commercial packaging




blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges

Click here